CloudLinux Inc. Launches a New Product in its Hosting Product Line — CloudLinux OS Solo
CloudLinux Inc., the team behind creating the popular CloudLinux operating system used extensively in the hosting community, announces the release of CloudLinux OS Solo. This is a new step for the hosting market, a new low-cost operating system that optimizes Linux server and application performance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005624/en/
Try a new operating system for your single user account for free and optimize your server and website performance. (Graphic: Business Wire)
Direct speech from CloudLinux Product team:
What was the motivation behind developing a new Operating System?
“Our starting point was clear. Based on research results, our clients overwhelmingly want the classic CloudLinux OS with VPS and VMs, which only a few users can then utilize. One main request is a robust set of CloudLinux features on one server at affordable prices. Consequently, we found hundreds of VPSs with five or fewer websites hosted by a single client, many of which use VMs for staging and production. Some clients want a stable OS with technical support that is secure and not open-sourced.”
CloudLinux OS Solo is a low-cost Linux OS for small businesses and any individual with just one hosting account which is maintained with 24/7 support. It is optimized for website and server performance, with features most needed to maintain online business stability.
What does the new CloudLinux OS Solo do? It detects server and website performance bottlenecks that can slow down customer business flow. There is also a substantial array of notifications and alerts that help users quickly detail server performance issues.
Moreover, the new OS focuses on domains' availability and responsiveness and has a PHP Slow Site analyzer that generates daily reports for the server administrator with information about the top slow PHP-based URLs for all domains. And PHP X-Ray identifying the slow CMS plugins, which ultimately speeds up the website. The new CloudLinux OS Solo also shows detailed information about database errors caused by slow queries, fixes code that causes slow functions, and slow external calls.
More features focused on website optimization will be available soon with the CloudLinux OS Solo. For example, single-click WordPress optimization will increase productivity, and together with Smart Advice, will help to improve website performance metrics, which is so important for online businesses.
Who will use CloudLinux OS Solo? Hosting providers who provide VPS and want to increase the upsell opportunities, product portfolio expansion, and a decrease in performance complaints. Small businesses and any individual with just one hosting account who want to speed up their online business and care about SEO metrics, value a fast and optimized website from a high-performed web server. CloudLinux OS Solo is fully automated (works out of the box), has 24/7 support from trusted vendor CloudLinux, and is compatible with all popular hosting software.
About CloudLinux Inc.
As an industry leader, CloudLinux persistently keeps up with server security issues that influence Linux server device stability and availability. Based in Palo Alto, California, the heart of Silicon Valley, CloudLinux develops a strengthened Linux distribution.
CloudLinux offers live security patching for all Linux kernels and extended support options for all distros. The robust Linux product offerings increase server security and software used by enterprises, service providers, governments, and universities worldwide.
To date, CloudLinux Inc. has over 500,000 product installations with more than 4,000 customers and partners globally. As a top provider of Linux-based software options, CloudLinux, prides itself on industry-leading customer service supported by technicians with 450 years of combined Linux experience.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005624/en/
Contact information
Kateryna Obiidykhata
Head of Marketing at CloudLinux Inc.
kobiidykhata@cloudlinux.com
+1 (800) 231-7307
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new
MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release
The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom